Cargando…

Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections

Intravitreal anti–vascular endothelial growth factor (anti-VEGF) agents have been increasingly applied in the treatment of retinal neovascular diseases. Concerns have arisen that these intravitreal agents may be associated with a potential risk of arterial thromboembolic (ATE) events. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, Yun-I., Chang, Hao-Yun, Lin, Meng-Yin, Tseng, Ching-Han, Wang, Tsung-Jen, Lin, I-Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172364/ https://www.ncbi.nlm.nih.gov/pubmed/37165045 http://dx.doi.org/10.1038/s41598-023-34128-5

Ejemplares similares

Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population‐based cohort study
por: Chang, Yin-Hsi, et al.
Publicado: (2022)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Effects of a Single Intravitreal Injection of Aflibercept and Ranibizumab on Glomeruli of Monkeys
por: Tschulakow, Alexander, et al.
Publicado: (2014)

Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection
por: Bilgin, Burak, et al.
Publicado: (2019)

The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes
por: Karakurt, Yucel, et al.
Publicado: (2018)

Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness
por: Ahn, Jayoung, et al.
Publicado: (2021)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Result of intravitreal aflibercept injection for myopic choroidal neovascularization
por: Chen, Shih-Lin, et al.
Publicado: (2021)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
por: Urban, Beata, et al.
Publicado: (2020)

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
por: Fujii, Ayaka, et al.
Publicado: (2014)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation
por: Raevis, Joseph J., et al.
Publicado: (2022)

Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study
por: Kishishita, Shuta, et al.
Publicado: (2022)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
por: Makri, Olga E, et al.
Publicado: (2018)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation
por: Chou, Hung-Da, et al.
Publicado: (2017)

Three-Year Outcomes of Intravitreal Aflibercept Injections for Retinal Angiomatous Proliferation According to Disease Stage
por: Huang, Ya-Yun, et al.
Publicado: (2022)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Erratum to: short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation
por: Chou, Hung-Da, et al.
Publicado: (2017)

Combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections for patients with diabetic macular edema refractory to intravitreal ranibizumab monotherapy
por: Chiu, Chiung-Yi, et al.
Publicado: (2021)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2017)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Long-Term Management of Complications of Retinal Artery Macroaneurysms with Intravitreal Aflibercept Injection
por: Kishore, Kamal
Publicado: (2016)

Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
por: Kanra, Ayse Yagmur, et al.
Publicado: (2018)

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Matsubara, Hisashi, et al.
Publicado: (2016)

Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
por: Vedantham, Vasumathy
Publicado: (2019)

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020)

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection
por: Suren, Elcin, et al.
Publicado: (2020)

Posterior scleritis after biweekly aflibercept intravitreal injections
por: Hébert, Mélanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ct24i4lhn7bofsp6isore6q20t